What is Zacks Research’s Forecast for PCRX FY2027 Earnings?

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of Pacira BioSciences in a research report issued to clients and investors on Thursday, March 20th. Zacks Research analyst R. Department anticipates that the company will post earnings of $2.45 per share for the year. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.41 per share.

PCRX has been the subject of several other reports. Needham & Company LLC upped their target price on shares of Pacira BioSciences from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, February 28th. HC Wainwright lifted their target price on Pacira BioSciences from $57.00 to $70.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Barclays increased their price target on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a report on Friday, February 28th. Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and increased their target price for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $18.00 price target on shares of Pacira BioSciences in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $27.22.

Pacira BioSciences Trading Up 2.9 %

NASDAQ PCRX opened at $24.84 on Monday. The company’s 50 day moving average price is $24.52 and its 200 day moving average price is $19.68. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -12.24 and a beta of 0.86. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. Pacira BioSciences has a one year low of $11.16 and a one year high of $31.67.

Institutional Trading of Pacira BioSciences

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Sterling Capital Management LLC lifted its stake in Pacira BioSciences by 779.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock worth $26,000 after acquiring an additional 1,208 shares in the last quarter. Ancora Advisors LLC bought a new stake in Pacira BioSciences in the fourth quarter worth approximately $26,000. Caitlin John LLC lifted its stake in shares of Pacira BioSciences by 1,850.0% in the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after purchasing an additional 1,776 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in Pacira BioSciences by 495.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after purchasing an additional 2,749 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in Pacira BioSciences by 16.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock valued at $68,000 after buying an additional 513 shares in the last quarter. Institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.